Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone Lymphoma

Video

In Partnership With:

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the accelerated FDA approval of ibrutinib (Imbruvica) as a treatment for patients with advanced marginal zone lymphoma (MZL).

The approval for ibrutinib in MZL was based on findings from an open-label phase II study. The objective response rates with ibrutinib was 46%, with a complete response rate of 3.2%, according to findings presented at the 2016 ASH Annual Meeting. The median progression-free survival was 14.2 months with ibrutinib (95% CI, 8.3-NR) and the median overall survival was not yet reached at a median follow-up of 19.4 months.

The accelerated approval for MZL is contingent upon findings from a larger confirmatory study and helps to fill an unmet medical need for patients with MZL. Further studies will continue to assess the safety and efficacy of the BTK inhibitor for patients with MZL.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD